Cytokinetics.
company in South San Francisco, United States
- Reports this week
- 3
- Active events
- 3
- Connections
- 58
What's happening
Active this week
-
Price targets for UDR were adjusted by Cantor Fitzgerald, Scotiabank, and Royal Bank of Canada on May 26, 2026.Well supported10 reports
-
The FDA has approved a drug developed by Cytokinetics for its intended use as a treatment.Some support3 reports1 development inside
-
Product Myqorzo received FDA approval.Some support1 report
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
MarketBeat is aggregating consensus ratings for Cytokinetics, while Bank of America provided a neutral rating and Morgan Stanley raised its target price.Some support2 reports
-
Cytokinetics is based in South San Francisco.Some support1 report
-
Cytokinetics achieved the first commercial launch of its drug in Germany, enabled by approval from the European Commission.Some support1 report
-
Yasmeen Rahimi maintained a Buy rating on Cytokinetics on July 6, 2025.Speculative1 report
-
Zymeworks and Cytokinetics are companies operating in the medical/biomedical sector.Some support1 report
-
Cytokinetics announced a revenue forecast growth of 54% per annum.Some support1 report
-
A career profile of James M. Daly detailing his appointments at Cytokinetics, Amgen, and GlaxoSmithKline.Some support1 report
-
Cytokinetics complied with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants on August 20, 2025.Some support3 reports
-
Rezolute, Inc. appointed Sunil Karnawat as Chief Commercial Officer, following his previous roles at Cytokinetics, Novo Nordisk, and Johnson & Johnson.Some support1 report
-
Cytokinetics and Pfizer announced strong US sales growth for Camzyos and a co-development agreement for Eliquis.Some support1 report
-
Cytokinetics management attended a conference on August 28, 2025, in both Boston and Everett.Some support1 report
-
Cytokinetics' drug is under FDA review, with clinical data presented at a congress in Madrid, Spain.Some support1 report1 development inside
-
Cytokinetics developed and tested Aficamten, finding it superior to Metoprolol and calling into question reliance on beta-blockers.Some support1 report
-
Cytokinetics presented study results at the European Society of Cardiology Congress in Madrid, Spain.Well supported6 reports
-
The new event details several corporate developments, including mergers involving Air Lease and Apollo, and Elliott Management's stake acquisition in PepsiCo.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Cytokinetics this week
News at the entities that move Cytokinetics most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Cytokinetics
-
Morgan Stanley OperationalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Cytokinetics
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Cytokinetics
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Cytokinetics
-
European Commission StructuralA European Commission summit focused on strategic cooperation, minerals, and pivoting away from the United States toward the EU.Moves Cytokinetics
-
Bristol-Myers Squibb OperationalBristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Moves Cytokinetics
Connections
The 21 strongest of 58, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
representative Transactional
Representative purchased shares of Cytokinetics.
-
SEC Structural
Cytokinetics must comply with SEC regulations, specifically regarding Rule 10b5-1 trading plans.
-
Sung Lee Structural
Sung Lee serves as the Executive Vice President of Cytokinetics.
-
FDA Structural
Cytokinetics' commercial viability is formally dependent on the review, approval, and oversight of its products by the FDA.
-
Securities and Exchange Commission Structural
Cytokinetics is subject to formal regulatory requirements and compliance oversight by the Securities and Exchange Commission.
-
Bristol-Myers Squibb Operational
The companies are direct competitors in the development and market presence of medicines for Hypertrophic Cardiomyopathy (HCM).
-
EMA Structural
Cytokinetics is actively seeking marketing authorization from the EMA.
-
Gil Cisneros Transactional
Gil Cisneros acquired shares of Cytokinetics.
Show all 21 connections
-
Morgan Stanley Operational
Morgan Stanley raised its target price for Cytokinetics stock, signaling market confidence in Cytokinetics' value.
-
European Commission Structural
The European Commission's regulatory approval enables Cytokinetics' market entry into Europe.
-
Bank of Montreal Transactional
Bank of Montreal raised its investment holdings in Cytokinetics.
-
European Society of Cardiology Mentioned together
Cytokinetics utilizes the European Society of Cardiology as a platform to present clinical trial results and investor updates.
-
Spain Shared context
Cytokinetics conducted presentations and announced data at a congress held in Spain.
-
Europe Structural
Cytokinetics is gaining regulatory approval and establishing market presence in Europe.
-
Stifel Mentioned together
Stifel provides market commentary and analysis regarding Cytokinetics' stock performance and clinical data.
-
South San Francisco Shared context
The company is geographically situated within the boundaries of South San Francisco.
-
MarketBeat Mentioned together
MarketBeat aggregates and reports consensus ratings regarding Cytokinetics.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada has cut its price target for Cytokinetics shares.
-
Bank of America Mentioned together
Bank of America provided a neutral rating on Cytokinetics shares.
-
Nasdaq Mentioned together
Cytokinetics stock rating is observed within the context of the Nasdaq market.
-
Novartis Transactional
Novartis is identified as a potential buyer of Cytokinetics' Myqorzo asset.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
1 eventJuly 2026
1 eventShow 1 earlier month
June 2026
18 events- Price targets for UDR were adjusted by Cantor Fitzgerald, Scotiabank, and Royal Bank of Canada on May 26, 2026.
- The FDA has approved a drug developed by Cytokinetics for its intended use as a treatment.
- Cytokinetics filed required disclosures with the SEC under a Rule 10b5-1 trading plan on June 23, 2026.
- MarketBeat is aggregating consensus ratings for Cytokinetics, while Bank of America provided a neutral rating and Morgan Stanley raised its target price.
- Cytokinetics is based in South San Francisco.
- Cytokinetics achieved the first commercial launch of its drug in Germany, enabled by approval from the European Commission.
- Yasmeen Rahimi maintained a Buy rating on Cytokinetics on July 6, 2025.
- Zymeworks and Cytokinetics are companies operating in the medical/biomedical sector.
- Cytokinetics announced a revenue forecast growth of 54% per annum.
- A career profile of James M. Daly detailing his appointments at Cytokinetics, Amgen, and GlaxoSmithKline.
- Cytokinetics complied with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants on August 20, 2025.
- Rezolute, Inc. appointed Sunil Karnawat as Chief Commercial Officer, following his previous roles at Cytokinetics, Novo Nordisk, and Johnson & Johnson.
- Cytokinetics and Pfizer announced strong US sales growth for Camzyos and a co-development agreement for Eliquis.
- Cytokinetics management attended a conference on August 28, 2025, in both Boston and Everett.
- Cytokinetics' drug is under FDA review, with clinical data presented at a congress in Madrid, Spain.
- Cytokinetics developed and tested Aficamten, finding it superior to Metoprolol and calling into question reliance on beta-blockers.
- Cytokinetics presented study results at the European Society of Cardiology Congress in Madrid, Spain.
- The new event details several corporate developments, including mergers involving Air Lease and Apollo, and Elliott Management's stake acquisition in PepsiCo.